The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|November 15, 2018
- Pharmaceutical Technology-11-15-2018
- Volume 2018 eBook
- Issue 2
Precompetitive Research Spurs Innovation in Pharmaceutical Analysis
Author(s)Jennifer Markarian
Industry–academia collaborations seek to address unmet needs in measurement science.
Advertisement
Precompetitive research is increasingly being considered as a cost-effective way to find solutions to widespread problems in the bio/pharmaceutical industry. Pharmaceutical Technology spoke with Christopher Welch, PhD, director of the Indiana Consortium for Analytical Sciences and Engineering (a joint venture between Purdue University, the University of Notre Dame, and Indiana University), about trends in pharmaceutical analysis and the consortium’s proposed Center for Bioanalytic Metrology, sponsored by the National Science Foundation.
Article Details
Pharmaceutical Technology
eBook: Best Practices for Today's Bio/Pharma Laboratory 2018
Vol. 42
November 2018
Pages: 10–13
Citation
When referring to this article, please cite it as J. Markarian, "Precompetitive Research Spurs Innovation in Pharmaceutical Analysis," Best Practices for Today's Bio/Pharma Laboratory 2018 eBook (November 2018).
Articles in this issue
almost 8 years ago
Cobots in the Pharma Labalmost 8 years ago
Analytical Best Practices for Raw Materials Testingalmost 8 years ago
Complex Protein Studies Demand Dynamic Techniquesalmost 8 years ago
Barriers and Solutions to Effective External Collaboration in Biopharmaalmost 8 years ago
Best Practices in Analytical Method Development and Testingalmost 8 years ago
Mixed Reality Gains a Foothold in the LabAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement